Moderna said on Thursday it was on track to report early data from a late-stage trial of its experimental Covid-19 vaccine in November, offering the clearest timeline yet for when the world will know whether it is effective.

The company, one of the front-runners in the global race to produce vaccines to protect against Covid-19, said an independent data monitoring committee was expected to conduct an interim review of its ongoing 30,000-person trial in November. Its shares rose 3%...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.